AZD9838 / AstraZeneca - LARVOL DELTA

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial. (PubMed, Vaccine) - "By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg)."

Clinical • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARTEMIS-C: A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (clinicaltrials.gov) - P1 | N=243 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARTEMIS-C: A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (clinicaltrials.gov) - P1 | N=243 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARTEMIS-C: A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: AstraZeneca | N=90 ➔ 240

Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARTEMIS-C: A Randomized Trial Evaluating a mRNA VLP Vaccine's Immunogenicity and Safety for COVID-19 (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases